These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1420 related articles for article (PubMed ID: 19644846)
21. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Verstappen SM; van Albada-Kuipers GA; Bijlsma JW; Blaauw AA; Schenk Y; Haanen HC; Jacobs JW; Ann Rheum Dis; 2005 Jan; 64(1):38-43. PubMed ID: 15130899 [TBL] [Abstract][Full Text] [Related]
22. Therapeutic strategies in rheumatoid arthritis over a 40-year period. Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636 [TBL] [Abstract][Full Text] [Related]
23. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial. Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105 [TBL] [Abstract][Full Text] [Related]
24. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway. Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766 [TBL] [Abstract][Full Text] [Related]
25. Lag time between onset of symptoms and access to rheumatology care and DMARD therapy in a cohort of patients with rheumatoid arthritis. Hernández-García C; Vargas E; Abásolo L; Lajas C; Bellajdell B; Morado IC; Macarrón P; Pato E; Fernández-Gutiérrez B; Bañares A; Jover JA J Rheumatol; 2000 Oct; 27(10):2323-8. PubMed ID: 11036824 [TBL] [Abstract][Full Text] [Related]
26. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Hakala M; Järvinen P; Ahonen J; Forsberg S; Leirisalo-Repo M; Arthritis Rheum; 2005 Jan; 52(1):36-41. PubMed ID: 15641055 [TBL] [Abstract][Full Text] [Related]
27. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study. Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308 [TBL] [Abstract][Full Text] [Related]
28. Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH). Kuriya B; Xiong J; Boire G; Haraoui B; Hitchon C; Pope J; Thorne JC; Tin D; Keystone EC; Bykerk V; J Rheumatol; 2014 Nov; 41(11):2161-6. PubMed ID: 25274902 [TBL] [Abstract][Full Text] [Related]
29. Absent "Window of Opportunity" in smokers with short disease duration. Data from BARFOT, a multicenter study of early rheumatoid arthritis. Söderlin MK; Bergman S; J Rheumatol; 2011 Oct; 38(10):2160-8. PubMed ID: 21807778 [TBL] [Abstract][Full Text] [Related]
30. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519 [TBL] [Abstract][Full Text] [Related]
31. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739 [TBL] [Abstract][Full Text] [Related]
32. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Welsing PM; Fransen J; van Riel PL Arthritis Rheum; 2005 Sep; 52(9):2616-24. PubMed ID: 16142762 [TBL] [Abstract][Full Text] [Related]
33. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102 [TBL] [Abstract][Full Text] [Related]
34. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829 [TBL] [Abstract][Full Text] [Related]
35. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. de Punder YM; Fransen J; Kievit W; Houtman PM; Visser H; van de Laar MA; van Riel PL Rheumatology (Oxford); 2012 Sep; 51(9):1610-7. PubMed ID: 22539487 [TBL] [Abstract][Full Text] [Related]
36. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort. Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE; J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342 [TBL] [Abstract][Full Text] [Related]
37. Combining anti-cyclic citrullinated peptide with the American College of Rheumatology 1987 criteria failed to improve early rheumatoid arthritis diagnosis in the community-based very early arthritis cohort. Le Loët X; Strotz V; Lequerré T; Boumier P; Pouplin S; Mejjad O; Daragon A; Jouen F; Vittecoq O; Fardellone P; Ménard JF Rheumatology (Oxford); 2011 Oct; 50(10):1901-7. PubMed ID: 21750000 [TBL] [Abstract][Full Text] [Related]
38. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. Gonzalez-Alvaro I; Carmona L; Balsa A; Sanmarti R; Belmonte MA; Tena X; J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186 [TBL] [Abstract][Full Text] [Related]
39. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Lee HS; Irigoyen P; Kern M; Lee A; Batliwalla F; Khalili H; Wolfe F; Lum RF; Massarotti E; Weisman M; Bombardier C; Karlson EW; Criswell LA; Vlietinck R; Gregersen PK Arthritis Rheum; 2007 Jun; 56(6):1745-53. PubMed ID: 17530703 [TBL] [Abstract][Full Text] [Related]
40. Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis. Yu X; Wang L; Xu P; Lu W; Lan G; Ping L; Wang X; Tian J; Liu J J Rheumatol; 2012 Jun; 39(6):1171-8. PubMed ID: 22505700 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]